Staffan Schüberg

Staffan Schüberg currently works at Corporación Químico Farmaceútica Esteve SA, as Chief Executive Officer, Esteve Healthcare SL, as Chief Executive Officer & Director from 2019, Esteve Pharmaceuticals SA, as Chief Executive Officer & Director from 2018, Pharmaceutical Research & Manufacturers of America, as Director from 2010, Swedish Orphan Biovitrum AB, as Independent Director from 2020, Dizlin Medical Design AB, as Director, Pensa Investments SL, as Director from 2020, and Dizlin Pharmaceuticals AB, as Director from 2015.
Mr. Schüberg also formerly worked at Lundbeck, Inc. (Illinois), as Chairman & President, Chelsea Therapeutics International Ltd., as President & Director, Lundbeck Portugal - Produtos Farmacêuticos Unipessoal Lda., as Managing Director, Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., as Director from 2019 to 2024, H.
Lundbeck A, as Chief Commercial Officer & Executive VP from 1995 to 2017, and Lundbeck USA Inc., as President.
Mr. Schüberg received his undergraduate degree from London Guildhall University.